Marina Rodnina joins IMB’s Scientific Advisory Board


5 April – The Institute of Molecular Biology (IMB) is pleased to welcome Prof. Marina Rodnina to its Scientific Advisory Board (SAB). Marina is the Director of Physical Biochemistry at the Max Planck Institute for Biophysical Chemistry in Göttingen and a renowned expert in ribosome function and mRNA translation.

Prof. Rodnina is best known for her work in deciphering the dynamics of ribosome function. Her lab investigates how different components of the ribosome interact and communicate with each other to facilitate the movement of tRNAs and mRNA through the ribosome during translation. In particular, she is interested in how these ribosomal reactions ensure that mRNAs are translated into proteins accurately and rapidly. Marina’s expertise and experience will be an invaluable asset for IMB and we look forward to welcoming her to our SAB.

IMB’s SAB is comprised of seven internationally renowned researchers, who are typically directors of research institutes. The board visits IMB each year to review its achievements and to provide valuable advice and recommendations on the institute’s strategic research directions and management, as well as recruitment and career development programmes for junior scientists.

Further details

Further information about the members of the SAB can be found at www.imb.de/about-imb/sab.  

About the Institute of Molecular Biology gGmbH

The Institute of Molecular Biology gGmbH (IMB) is a centre of excellence in the life sciences that was established in 2011 on the campus of Johannes Gutenberg University Mainz (JGU). Research at IMB focuses on the cutting-edge fields of epigenetics, genome stability, ageing and RNA biology. The institute is a prime example of successful collaboration between a private foundation and government: The Boehringer Ingelheim Foundation has committed 154 million euros to be disbursed from 2009 until 2027 to cover the operating costs of research at IMB. The State of Rhineland-Palatinate has provided approximately 50 million euros for the construction of a state-of-the-art building and is giving a further 52 million in core funding from 2020 until 2027. For more information about IMB, please visit: www.imb.de.

Boehringer Ingelheim Foundation

The Boehringer Ingelheim Foundation is an independent, non-profit organization that is committed to the promotion of the medical, biological, chemical, and pharmaceutical sciences. It was established in 1977 by Hubertus Liebrecht (1931–1991), a member of the shareholder family of the Boehringer Ingelheim company. Through its Perspectives Programme Plus 3 and its Exploration Grants, the Foundation supports independent junior group leaders. It also endows the international Heinrich Wieland Prize, as well as awards for up-and-coming scientists in Germany. In addition, the Foundation funds institutional projects in Germany, such as the Institute of Molecular Biology (IMB), the department of life sciences at the University of Mainz, and the European Molecular Biology Laboratory (EMBL) in Heidelberg. www.bistiftung.de.

Press contact for further information

Dr Ralf Dahm, Director of Scientific Management

Institute of Molecular Biology gGmbH (IMB), Ackermannweg 4, 55128 Mainz, Germany

Phone: +49 (0) 6131 39 21455, Email: press(at)imb.de